Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

157.30 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, May 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Marjorie Taylor Greene Goes Stock Shopping Again: Here Are 50+ Stocks The Congresswoman Bought
Marjorie Taylor Greene disclosed buying more than 50 stocks in early May. A look at the list and why the congresswoman's past trades have drawn red flags. 
Via Benzinga
Recent Filing Shows That Rep. Gilbert Ray Cisneros Bought Over $106K Worth of Aris Water Solutions Stock
Via Benzinga
FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight
FDA to increase surprise inspections at foreign facilities as U.S. companies pour billions into domestic drug and device manufacturing. 
Via Benzinga
Exposures Product Safety
Trump Orders FDA To Fast-Track US Drug Production As Tariff Threat Looms On Imported Medicines: Cites National Security Concerns
President Donald Trump signed an executive order Monday directing the FDA to accelerate approvals for domestic pharmaceutical manufacturing facilities as his administration prepares to announce new... 
Via Benzinga
Topics Government World Trade
Exposures Political Product Safety Tariff
Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday?
FDA approves Teva and Alvotech's Selarsdi as an interchangeable biosimilar to Stelara, supporting the treatment of multiple chronic inflammatory diseases. 
Via Benzinga
Exposures Product Safety
Donald Trump Vows To 'Call' Up CEOs Who Make Business Moves That Displease Him, Explains Why He Phoned Jeff Bezos To Scrap Amazon's Tariff Disclosure
Trump claims he might personally phone CEOs for business moves he dislikes, using this tactic on Amazon's Bezos over tariff disclosures. 
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
Analyzing JOHNSON & JOHNSON (NYSE:JNJ)'s Dividend Potential.
Why JOHNSON & JOHNSON (NYSE:JNJ) provides a good dividend, while having solid fundamentals. 
Via Chartmill
Here Are All the Dividend Kings Beating the S&P 500 in 2025 -- and the 2 That Are the Best Stocks to Buy Now
Via The Motley Fool
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
Is the Trump Administration About to Cause AbbVie, Eli Lilly, and Johnson & Johnson Stocks to Crash?
Via The Motley Fool
Topics Earnings Economy Government
Exposures Financial Political Supply Chain
Johnson & Johnson - Elliott Wave Technical Analysis
We are tracking a potential major bottom forming in Primary wave 2. A clear five-wave move into wave {i} suggests the early stages of an upside trend resumption. 
Via Talk Markets
40-Year-Old Making $4K a Month in Dividends Reveals His Top 8 Stocks — 'We Don't Wear Fancy Clothes or Spend Money on Impressing Others'
Via Benzinga
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
If A Recession Hits, Will Medical Stocks Be A Safe Haven For Investors — Again?
Medical stocks are usually considered defensive. But have they been too hammered by regulatory changes to hold up this year? 
Via Investor's Business Daily
Topics Animal Testing Economy Government
Exposures Animal Testing Economy Political
Nvidia, Johnson & Johnson, Hyundai, Toyota, SoftBank CEOs To Join Trump At White House As He Touts Investment Surge In First 100 Days: Report
Trump to highlight investments from top companies, including Nvidia, J&J, and Toyota, in 'Investing in America' event to mark first 100 days in office. 
Via Benzinga
Topics Government
Exposures Political
Plaintiff Sues Eli Lilly, Johnson & Johnson Over Alleged Breast Cancer Risk Linked To Antipsychotic Medications
A lawsuit claims Eli Lilly, Johnson & Johnson, and Kaiser Permanente failed to warn consumers about breast cancer risks linked to their antipsychotic drugs Risperdal and Zyprexa. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
AbbVie Immunology Portfolio Poised For Growth Through Humira Erosion: Analyst
Analysts raise AbbVie price targets after strong Q1 results, driven by Skyrizi, Rinvoq growth and strategic moves in Parkinson's disease treatments. 
Via Benzinga
CG Oncology Rockets On Its Johnson & Johnson-Rivaling Cancer Drug
The companies are working on treatments for a form of bladder cancer. 
Via Investor's Business Daily
3 Industry Behemoths Are Rewarding Investors With Dividend Bumps
See these three stocks that are among the most important in their industries, which have announced sizable increases in their dividends. 
Via MarketBeat
Topics World Trade
Exposures Tariff
3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.
See these three top-10 stocks in the pharmaceutical industry that are pledging investment in the United States totalling over $100 billion. 
Via MarketBeat
Topics Artificial Intelligence Economy Government
Exposures Artificial Intelligence Economy Political
These 2 Top Dividend Stocks Are Making Moves to Avoid the Impact of Tariffs: Are They Buys?
Via The Motley Fool
Topics Economy Government Lawsuit
Exposures Financial Interest Rates Legal
3 Dividend Kings That Have Raised Their Payouts in 2025
Via The Motley Fool
Topics Economy
Exposures Interest Rates
In the Wake of the Trump Tariff Crash: 2 Unparalleled Dividend Stocks to Buy at a Discount Right Now
Short-term tariff uncertainty marks the perfect opportunity for long-term investors to snag some amazing deals. 
Via The Motley Fool
Topics Economy Government Stocks
Exposures Interest Rates Political Tariff
Merck (MRK) Reports Q1: Everything You Need To Know Ahead Of Earnings
Global pharmaceutical company Merck (NYSE:MRK) will be reporting results tomorrow before market hours. Here’s what to expect. 
Via StockStory
Bristol-Myers Squibb (BMY) Reports Earnings Tomorrow: What To Expect
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be announcing earnings results tomorrow morning. Here’s what investors should know. 
Via StockStory
Trump Administration Considers Lowering US Drug Prices To International Levels: Report
The Trump Administration is reportedly mulling over a policy to match U.S. drug prices with those in other developed nations. 
Via Benzinga
Topics Government
Exposures Political
JNJ Q1 Earnings: Pipeline Progress and MedTech Execution Drive Guidance Above Expectations
Multinational healthcare company Johnson & Johnson (NYSE:JNJ) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 2.4% year on year to $21.89 billion. The company’s full-year revenue... 
Via StockStory
Topics Earnings World Trade
Exposures Financial Tariff
Why Johnson & Johnson, Chevron, And Flowers Foods Are Winners For Passive Income
Via Benzinga
Roche Plans $50 Billion US Investment Over 5 Years With 12,000 New Jobs
Roche to invest $50 billion in U.S. over five years, adding 12,000+ jobs and expanding manufacturing, R&D, and export capacity across eight states. 
Via Benzinga
9 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Johnson & Johnson (JNJ): Buy, Sell, or Hold Post Q1 Earnings?
Johnson & Johnson has been treading water for the past six months, recording a small loss of 3.8% while holding steady at $157.30. However, the stock is beating the S&P 500’s 11% decline during that... 
Via StockStory
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.